Company intelligence / Profile preview

Cleveland Diagnostics

Cleveland, Ohio, United States

Ownership: Private
Development stage: Commercial

Overview

Cleveland Diagnostics’ lead product, IsoPSA, has demonstrated high sensitivity and specificity for detecting prostate cancer compared to traditional PSA tests. Clinical studies show it can reduce unnecessary prostate biopsies by up to 55%. The company’s technology has been validated in peer-reviewed publications and the test is available nationwide with Medicare coverage. Additional diagnostics for other cancers are under development

Therapeutic areas: Oncology
Modalities: Device (diagnostic test)Protein-based diagnostic
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

IsoPSA

Commercial

Indications: Prostate cancer

Partnerships

Quest Diagnostics—distribution agreement for national access to IsoPSA testJobsOhio—economic support partnershipNovo Holdings—lead investor/supporter

Beyond the preview

Go deeper on Cleveland Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cleveland Diagnostics.

Explore the full profile